Author + information
To study the expressions of chemokine CCL2 in plasma and platelets of patients with STEMI, and to investigate the effect of CCL2 on P65 and IκBα in the signal pathway of NF-κB.
We detected plasma CCL2 concentration of patients with STEMI and controls by Elisa, 50 cases were in each group; Expressions of CCL2 and CCR2 in the platelets were detected by western blot; Phosphorylations of P65 and IκBα expression in the platelets were tested by western blot after CCL2 stimulation, or were tested while CCR2 antagonist RS201895 and NF-κB signaling pathway inhibitor Bay11-7082 were pretreated with the platelets.
The plasma CCL2 concentration of STEMI patients was 217±100 pg/ml, the plasma CCL2 concentration of controls was 167±31 pg/ml (p<0.01). Compared with control group, the expressions of CCL2 and CCR2 in the platelets were significantly increased in STEMI patients (p<0.01). After the platelets were stimulated by CCL2, pP65 increased and IκBα decreased (P<0.01); if RS201895 or Bay11-7082 were applied before CCL2 stimulation, pP65 decreased and IκBα increased (P<0.01).
The expressions of CCL2 in plasma and platelets of patients with STEMI increased. CCL2/CCR2 might affect the functions of platelets through NF-κB signaling pathway, and participate in thrombosis.